259 related articles for article (PubMed ID: 28293280)
1. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.
Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
Biopsychosoc Med; 2017; 11():7. PubMed ID: 28293280
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.
Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
Biopsychosoc Med; 2017; 11():8. PubMed ID: 28331539
[TBL] [Abstract][Full Text] [Related]
3. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
[TBL] [Abstract][Full Text] [Related]
4. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
[TBL] [Abstract][Full Text] [Related]
5. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
Tomita T; Fukui H; Morishita D; Mori S; Oshima T; Shinzaki S; Miwa H
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498457
[TBL] [Abstract][Full Text] [Related]
7. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Hayashi K; Akiho H; Nakashima Y; Haruma K
J Gastroenterol; 2016 Sep; 51(9):874-82. PubMed ID: 26800997
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
[TBL] [Abstract][Full Text] [Related]
9. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
Qi Q; Zhang Y; Chen F; Zuo X; Li Y
BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
[TBL] [Abstract][Full Text] [Related]
10. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Min YW; Rhee PL
Therap Adv Gastroenterol; 2015 May; 8(3):136-42. PubMed ID: 25949526
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.
Chiba T; Yamamoto K; Sato S; Suzuki K
Clin Exp Gastroenterol; 2013; 6():123-8. PubMed ID: 23922505
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
[TBL] [Abstract][Full Text] [Related]
13. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index.
Shinozaki M; Kanazawa M; Sagami Y; Endo Y; Hongo M; Drossman DA; Whitehead WE; Fukudo S
J Gastroenterol; 2006 May; 41(5):491-4. PubMed ID: 16799892
[TBL] [Abstract][Full Text] [Related]
15. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
16. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.
Brenner DM; Dove LS; Andrae DA; Covington PS; Gutman C; Chey WD
Neurogastroenterol Motil; 2018 Mar; ():e13331. PubMed ID: 29575372
[TBL] [Abstract][Full Text] [Related]
17. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study.
Niles SE; Blazy P; Cheuvront SN; Kenefick RW; Vidyasagar S; Smith AB; Fawkes N; Denman W
World J Gastrointest Pharmacol Ther; 2023 Dec; 14(5):39-49. PubMed ID: 38174291
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod for the treatment of irritable bowel syndrome.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
